Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolebrutinib in primary progressive multiple sclerosis
NCT04458051Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2020
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 42
01
Overview
A Phase 3 trial of tolebrutinib in primary progressive multiple sclerosis (PPMS), sponsored by Sanofi. Started Aug 2020; status: completed.
02
Drugs
tolebrutinib
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NCT04458051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04458051.